MedTrace Logo

Randomized Clinical Trial in Parkinson's Disease Patients Using Pluripotent Adipose Stem Cells (PASCs)

NCT06141317 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-12-01

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of allogenic pluripotent stem cells isolated from adipose tissue (PASCs) in patients with Parkinson's Disease.

Conditions

  • Parkinson Disease

Interventions

BIOLOGICAL

PASC transplantation (25 million PASCs/patient)

3 doses of 25 million PASCs implantation via peripheral vein (Day 0, 3 months, 6 months)

BIOLOGICAL

Control

0.9% saline solution via peripheral vein (Day 0, 3 months, 6 months)

Sponsors & Collaborators

Principal Investigators

  • Freddy Henriquez, M.D. · Hospital Clínica Católica

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-23
Primary Completion
2024-09-01
Completion
2024-11-01

Countries

  • Costa Rica

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06141317 on ClinicalTrials.gov